- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
LUGPA Will Create Bundled Payment Models for Prostate Care
November 8th 2016, 1:12am
The Large Urology Group Practice Association has announced the plan to create two alternative payment models that involve bundled payments.
Expert Emphasizes Impact of Robotic Surgery in Field of Prostate Cancer
November 8th 2016, 12:54am
David Albala, MD, discusses some of the benefits of robotic surgery and the impact it has had on the field of prostate cancer, as well as methods that larger urology groups can use to better achieve compliance.
Atezolizumab Combos Highly Effective for Advanced Melanoma
November 7th 2016, 11:11pm
The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.
Dr. Concepcion on the Use of Eligard in Prostate Cancer Treatment
November 7th 2016, 9:40pm
Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.
Dr. Buffington on The Use of Fusion MRI in Prostate Cancer
November 7th 2016, 8:58pm
Philip J. Buffington, MD, Chief Medical Officer, The Urology Group, discussed the use of fusion MRI in prostate cancer with OncLive during the LUGPA Annual Meeting.
Potential for Neoadjuvant Immunotherapy in Bladder Cancer Is Wide Open, Expert Says
November 7th 2016, 3:40am
With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.
Nimble, Larger Practices Can Thrive Under New Healthcare Delivery Models
November 7th 2016, 12:24am
Whatever the result of the US presidential election, the era ahead will continue to be one of unprecedented change in healthcare, according to Robert Laszewski.
Dr. David Albala on The Role of Robotic Surgery in Prostate Cancer
November 6th 2016, 10:37pm
Systemic Immunotherapy Use Expanding Rapidly in Bladder Cancer
November 6th 2016, 9:30pm
Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.
Lenvatinib Regimen Setting Pace for Emerging Combos in Kidney Cancer
November 6th 2016, 12:33am
The dual inhibitor combination of lenvatinib and everolimus is becoming an essential second-line treatment option in advanced renal cell carcinoma, and research to move the regimen into frontline settings is underway.
Novel Therapies Offer Hope for BCG-Unresponsive Bladder Cancer
November 5th 2016, 11:45pm
A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.
RCC Experts Consider Immunotherapy Integral to Optimizing Adjuvant Care
November 5th 2016, 11:23pm
Looking ahead to 2020, most participants on an expert panel projected that immunotherapy will be critical to optimizing outcomes in the adjuvant setting for patients with renal cell carcinoma.
Bladder Cancer Biomarkers Aid in Diagnosis, Monitoring
November 5th 2016, 10:19pm
When it comes to the burgeoning arena of biomarkers in bladder cancer, the value proposition is compelling, although the utility and costs need to be better defined, according to Badrinath Konety, MD, MBA.
Cabozantinib Benefits Similar in MET Expressing Advanced RCC
November 5th 2016, 9:36pm
Cabozantinib demonstrated consistent benefits compared with everolimus for patients with advanced, pretreated renal cell carcinoma in a subgroup analysis of the phase III METEOR trial that explored MET expression.
Dr. Hutson on Lenvatinib/Everolimus Combo in RCC
November 5th 2016, 5:48pm
Thomas E. Hutson, DO, PharmD, director of the Genitourinary Oncology Program, Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the efficacy associated with the combination of levantinib (Lenvima) and everolimus (Afinitor) in patients with metastatic renal cell carcinoma (RCC).
Dr. Haas on Adjuvant VEGF-Targeted Therapy in RCC
November 5th 2016, 5:00pm
Naomi B. Haas, MD, director, Prostate and Kidney Cancer Program Associate Professor of Medicine at the Hospital of the University of Pennsylvania, discusses results of 2 ongoing clinical trials looking at adjuvant therapy options in renal cell carcinoma (RCC).
Expert Examines Conflicting Adjuvant RCC Results
November 5th 2016, 4:31am
Conflicting results from large adjuvant studies for renal cell carcinoma may have been caused by differences between the clinical trial designs, patient populations, and assessment criteria.
Dr. Plimack on Significance of CheckMate-025 Trial in RCC
November 5th 2016, 2:04am
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.
Dr. Geoffrey Sklar On Immunotherapy Advancements in Bladder Cancer
November 5th 2016, 1:46am
Dr. Geoffrey Sklar, Chief Medical Officer, Chesapeake Urology Associates, spoke with OncLive about some of the exciting advancements in bladder cancer during the LUGPA Annual Meeting.
Expert Discusses Neoadjuvant Treatment Potential in Advanced RCC
November 5th 2016, 1:40am
Neoadjuvant therapy is evolving as a treatment approach for patients with advanced renal cell carcinoma.